Pertussis and influenza immunisation during pregnancy: a landscape review

The Lancet Infectious Diseases

Volumn 17, Issue 7, 2017, Pages e209-e222

  Abu Raya, Bahaa ^a   Edwards, Kathryn M ^b   Scheifele, David W ^a   Halperin, Scott A ^c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c DALHOUSIE UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; PERTUSSIS VACCINE; DIPHTHERIA PERTUSSIS TETANUS VACCINE;

BORDETELLA PERTUSSIS; BREAST MILK; DISEASE BURDEN; HUMAN; HUMORAL IMMUNITY; INFLUENZA; INFLUENZA VACCINATION; MOTHER; PERTUSSIS; PLACENTAL TRANSFER; PREGNANCY; PRIORITY JOURNAL; REVIEW; FEMALE; IMMUNIZATION; IMMUNOLOGY; INFLUENZA, HUMAN; PASSIVE IMMUNIZATION; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; PROCEDURES; UTILIZATION; VACCINATION;

DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; FEMALE; HUMANS; IMMUNITY, MATERNALLY-ACQUIRED; IMMUNIZATION; INFLUENZA VACCINES; INFLUENZA, HUMAN; PERTUSSIS VACCINE; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PRENATAL CARE; VACCINATION;

EID: 85018617835     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(17)30190-1     Document Type: Review

References (131)

1. Neuzil, KM, Reed, GW, Mitchel, EF, Simonsen, L, Griffin, MR, Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 148 (1998), 1094–1102.
2. Thwaites, CL, Beeching, NJ, Newton, CR, Maternal and neonatal tetanus. Lancet 385 (2015), 362–370.
3. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap) in pregnant women—Advisory Committee on Immunization Practices (ACIP), 2012. MMWR Morb Mortal Wkly Rep 62 (2013), 131–135.
4. Marchant, A, Sadarangani, M, Garand, M, et al. Maternal immunisation: a worldwide landscape analysis. Lancet Infect Dis, 2017 published onlined April 19 http://dx.doi.org/10.1016/S1473-3099(17)30232-3.
5. Centers for Disease Control and Prevention. Pertussis epidemic—Washington, 2012. MMWR Morb Mortal Wkly Rep 61 (2012), 517–522.
6. Winter, K, Harriman, K, Zipprich, J, et al. California pertussis epidemic, 2010. J Pediatr 161 (2012), 1091–1096.
7. Winter, K, Glaser, C, Watt, J, Harriman, K, for the Centers for Disease Control and Prevention (CDC) Study Group. Pertussis epidemic—California, 2014. MMWR Morb Mortal Wkly Rep 63 (2014), 1129–1132.
8. Schanzer, DL, Langley, JM, Tam, TW, Influenza-attributed hospitalization rates among pregnant women in Canada 1994–2000. J Obstet Gynaecol Can 29 (2007), 622–629.
9. Siston, AM, Rasmussen, SA, Honein, MA, et al. Pandemic 2009 influenza A(H1N1) virus illness among pregnant women in the United States. JAMA 303 (2010), 1517–1525.
10. Kourtis, AP, Read, JS, Jamieson, DJ, Pregnancy and infection. N Engl J Med 370 (2014), 2211–2218.
11. Cherry, JD, Chang, SJ, Klein, D, et al. Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults. Clin Infect Dis 39 (2004), 1715–1718.
12. Bigham, M, Konrad, S, Van Buynder, P, et al. Low pertussis toxin antibody levels in two regional cohorts of Canadian pregnant women. Vaccine 32 (2014), 6493–6498.
13. Munoz, FM, Bond, NH, Maccato, M, et al. Safety and immunogenicity of tetanus diphtheria and acellular pertussis (Tdap) immunization during pregnancy in mothers and infants: a randomized clinical trial. JAMA 311 (2014), 1760–1769.
14. de Greeff, SC, Mooi, FR, Westerhof, A, et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis 50 (2010), 1339–1345.
15. Abu Raya, B, Srugo, I, Kessel, A, et al. The effect of timing of maternal tetanus, diphtheria, and acellular pertussis (Tdap) immunization during pregnancy on newborn pertussis antibody levels-a prospective study. Vaccine 32 (2014), 5787–5793.
16. Gall, SA, Myers, J, Pichichero, M, Maternal immunization with tetanus-diphtheria-pertussis vaccine: effect on maternal and neonatal serum antibody levels. Am J Obstet Gynecol, 204, 2011, 334 e1–e5.
17. Healy, CM, Rench, MA, Baker, CJ, Importance of timing of maternal combined tetanus, diphtheria, and acellular pertussis (Tdap) immunization and protection of young infants. Clin Infect Dis 56 (2013), 539–544.
18. Hardy-Fairbanks, AJ, Pan, SJ, Decker, MD, et al. Immune responses in infants whose mothers received Tdap vaccine during pregnancy. Pediatr Infect Dis J 32 (2013), 1257–1260.
19. Hoang, HT, Leuridan, E, Maertens, K, et al. Pertussis vaccination during pregnancy in Vietnam: results of a randomized controlled trial pertussis vaccination during pregnancy. Vaccine 34 (2016), 151–159.
20. Maertens, K, Caboré, RN, Huygen, K, Hens, N, Van Damme, P, Leuridan, E, Pertussis vaccination during pregnancy in Belgium: results of a prospective controlled cohort study. Vaccine 34 (2016), 142–150.
21. Abu Raya, B, Bamberger, E, Almog, M, Peri, R, Srugo, I, Kessel, A, Immunization of pregnant women against pertussis: the effect of timing on antibody avidity. Vaccine 33 (2015), 1948–1952.
22. Dalby, T, Petersen, JW, Harboe, ZB, Krogfelt, KA, Antibody responses to pertussis toxin display different kinetics after clinical Bordetella pertussis infection than after vaccination with an acellular pertussis vaccine. J Med Microbiol 59 (2010), 1029–1036.
23. McIntyre, PB, Burgess, MA, Egan, A, Schuerman, L, Hoet, B, Booster vaccination of adults with reduced-antigen-content diphtheria, tetanus and pertussis vaccine: immunogenicity 5 years post-vaccination. Vaccine 27 (2009), 1062–1066.
24. Halperin, BA, Morris, A, Mackinnon-Cameron, D, et al. Kinetics of the antibody response to tetanus-diphtheria-acellular pertussis vaccine in women of childbearing age and postpartum women. Clin Infect Dis 53 (2011), 885–892.
25. Abu Raya, B, Srugo, I, Kessel, A, Peterman, M, Vaknin, A, Bamberger, E, The decline of pertussis-specific antibodies after tetanus, diphtheria, and acellular pertussis immunization in late pregnancy. J Infect Dis 212 (2015), 1869–1873.
26. Huygen, K, Caboré, RN, Maertens, K, Van Damme, P, Leuridan, E, Humoral and cell mediated immune responses to a pertussis containing vaccine in pregnant and nonpregnant women. Vaccine 33 (2015), 4117–4123.
27. Blanchard-Rohner, G, Meier, S, Bel, M, et al. Influenza vaccination given at least 2 weeks before delivery to pregnant women facilitates transmission of seroprotective influenza-specific antibodies to the newborn. Pediatr Infect Dis J 32 (2013), 1374–1380.
28. Lin, SY, Wu, ET, Lin, CH, Shyu, MK, Lee, CN, The safety and immunogenicity of trivalent inactivated influenza vaccination: a study of maternal-cord blood pairs in Taiwan. PLoS One, 8, 2013, e62983.
29. Puleston, R, Bugg, G, Hoschler, K, et al. Multi-centre observational study of transplacental transmission of influenza antibodies following vaccination with AS03(A)-adjuvanted H1N1 2009 vaccine. PLoS One, 8, 2013, e47448.
30. Fisher, BM, Van Bockern, J, Hart, J, et al. Pandemic influenza A H1N1 2009 infection versus vaccination: a cohort study comparing immune responses in pregnancy. PLoS One, 7, 2012, e33048.
31. Sperling, RS, Engel, SM, Wallenstein, S, et al. Immunogenicity of trivalent inactivated influenza vaccination received during pregnancy or postpartum. Obstet Gynecol 119 (2012), 631–639.
32. Tsatsaris, V, Capitant, C, Schmitz, T, et al. Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial. Ann Intern Med 155 (2011), 733–741.
33. Jackson, LA, Patel, SM, Swamy, GK, et al. Immunogenicity of an inactivated monovalent 2009 H1N1 influenza vaccine in pregnant women. J Infect Dis 204 (2011), 854–863.
34. Ohfuji, S, Fukushima, W, Deguchi, M, et al. Immunogenicity of a monovalent 2009 influenza A (H1N1) vaccine among pregnant women: lowered antibody response by prior seasonal vaccination. J Infect Dis 203 (2011), 1301–1308.
35. Jackson, LA, Gaglani, MJ, Keyserling, HL, et al. Safety, efficacy, and immunogenicity of an inactivated influenza vaccine in healthy adults: a randomized, placebo-controlled trial over two influenza seasons. BMC Infect Dis, 10, 2010, 71.
36. Schlaudecker, EP, McNeal, MM, Dodd, CN, Ranz, JB, Steinhoff, MC, Pregnancy modifies the antibody response to trivalent influenza immunization. J Infect Dis 206 (2012), 1670–1673.
37. Bischoff, AL, Følsgaard, NV, Carson, CG, et al. Altered response to A(H1N1)pnd09 vaccination in pregnant women: a single blinded randomized controlled trial. PLoS One, 8, 2013, e56700.
38. Ludvigsson, JF, Zugna, D, Cnattingius, S, et al. Influenza H1N1 vaccination and adverse pregnancy outcome. Drug Saf 36 (2013), 455–465.
39. Rubinstein, F, Micone, P, Bonotti, A, et al. Influenza A/H1N1 MF59 adjuvanted vaccine in pregnant women and adverse perinatal outcomes: multicentre study. BMJ, 346, 2013, f393.
40. Heikkinen, T, Young, J, van Beek, E, et al. Safety of MF59-adjuvanted A/H1N1 influenza vaccine in pregnancy: a comparative cohort study. Am J Obstet Gynecol, 207, 2012, 177 e1–e8.
41. Kallen, B, Olausson, PO, Vaccination against H1N1 influenza with Pandemrix during pregnancy and delivery outcome: a Swedish register study. BJOG 119 (2012), 1583–1590.
42. Tavares, F, Nazareth, I, Monegal, JS, Kolte, I, Verstraeten, T, Bauchau, V, Pregnancy and safety outcomes in women vaccinated with an AS03-adjuvanted split virion H1N1 (2009) pandemic influenza vaccine during pregnancy: a prospective cohort study. Vaccine 29 (2011), 6358–6365.
43. Tsai, T, Kyaw, MH, Novicki, D, Nacci, P, Rai, S, Clemens, R, Exposure to MF59-adjuvanted influenza vaccines during pregnancy—a retrospective analysis. Vaccine 28 (2010), 1877–1880.
44. Madhi, SA, Cutland, CL, Kuwanda, L, et al. Influenza vaccination of pregnant women and protection of their infants. N Engl J Med 371 (2014), 918–931.
45. Nunes, MC, Cutland, CL, Dighero, B, et al. Kinetics of hemagglutination inhibiting antibodies following maternal influenza vaccination among mothers with and those without HIV infection and their infants. J Infect Dis 212 (2015), 1976–1987.
46. Nomura, M, Kuno-Sakai, H, Kimura, M, Ichikawa, I, Dynamics of transplacental transmission of pertussis antibodies in premature and full-term infants. Tokai J Exp Clin Med 28 (2003), 21–26.
47. Healy, CM, Rench, MA, Edwards, KM, Baker, CJ, Pertussis serostatus among neonates born to hispanic women. Clin Infect Dis 42 (2006), 1439–1442.
48. Plans, P, Jansà, J, Doshi, N, Harrison, TG, Plasència, A, Prevalence of pertussis antibodies in umbilical cord blood samples in Catalonia, Spain. Pediatr Infect Dis J 27 (2008), 1023–1025.
49. de Voer, RM, van der Klis, FR, Nooitgedagt, JE, et al. Seroprevalence and placental transportation of maternal antibodies specific for Neisseria meningitidis serogroup C, Haemophilus influenzae type B, diphtheria, tetanus, and pertussis. Clin Infect Dis 49 (2009), 58–64.
50. Nooitgedagt, JE, de Greeff, SC, Elvers, BH, et al. Seroprevalence of Bordetella pertussis infection during pregnancy measured by IgG antibodies against pertussis toxin. Clin Infect Dis 49 (2009), 1086–1089.
51. Shakib, JH, Ralston, S, Raissy, HH, Stoddard, GJ, Edwards, KM, Byington, CL, Pertussis antibodies in postpartum women and their newborns. J Perinatol 30 (2010), 93–97.
52. Heininger, U, Riffelmann, M, Leineweber, B, Wirsing von Koenig, CH, Maternally derived antibodies against Bordetella pertussis antigens pertussis toxin and filamentous hemagglutinin in preterm and full term newborns. Pediatr Infect Dis J 28 (2009), 443–445.
53. Ercan, TE, Sonmez, C, Vural, M, Erginoz, E, Torunoğlu, MA, Perk, Y, Seroprevalance of pertussis antibodies in maternal and cord blood of preterm and term infants. Vaccine 31 (2013), 4172–4176.
54. Healy, CM, Munoz, FM, Rench, MA, Halasa, NB, Edwards, KM, Baker, CJ, Prevalence of pertussis antibodies in maternal delivery, cord, and infant serum. J Infect Dis 190 (2004), 335–340.
55. Gonik, B, Puder, KS, Gonik, N, Kruger, M, Seroprevalence of Bordetella pertussis antibodies in mothers and their newborn infants. Infect Dis Obstet Gynecol 13 (2005), 59–61.
56. Leuridan, E, Hens, N, Peeters, N, de Witte, L, Van der Meeren, O, Van Damme, P, Effect of a prepregnancy pertussis booster dose on maternal antibody titers in young infants. Pediatr Infect Dis J 30 (2011), 608–610.
57. van den Berg, JP, Westerbeek, EA, Berbers, GA, van Gageldonk, PG, van der Klis, FR, van Elburg, RM, Transplacental transport of IgG antibodies specific for pertussis, diphtheria, tetanus, Haemophilus influenzae type b, and Neisseria meningitidis serogroup C is lower in preterm compared with term infants. Pediatr Infect Dis J 29 (2010), 801–805.
58. Mooi, FR, de Greeff, SC, The case for maternal vaccination against pertussis. Lancet Infect Dis 7 (2007), 614–624.
59. Englund, JA, The influence of maternal immunization on infant immune responses. J Comp Pathol 137:suppl 1 (2007), S16–S19.
60. Van Savage, J, Decker, MD, Edwards, KM, Sell, SH, Karzon, DT, Natural history of pertussis antibody in the infant and effect on vaccine response. J Infect Dis 161 (1990), 487–492.
61. Naidu, MA, Muljadi, R, Davies-Tuck, ML, Wallace, EM, Giles, ML, The optimal gestation for pertussis vaccination during pregnancy: a prospective cohort study. Am J Obstet Gynecol, 215, 2016, 237 e1–6.
62. Eberhardt, CS, Blanchard-Rohner, G, Lemaître, B, et al. Maternal immunization earlier in pregnancy maximizes antibody transfer and expected infant seropositivity against pertussis. Clin Infect Dis 62 (2016), 829–836.
63. Cherry, JD, Gornbein, J, Heininger, U, Stehr, K, A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 16 (1998), 1901–1906.
64. Storsaeter, J, Hallander, HO, Gustafsson, L, Olin, P, Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 16 (1998), 1907–1916.
65. Taranger, J, Trollfors, B, Lagergård, T, et al. Correlation between pertussis toxin IgG antibodies in postvaccination sera and subsequent protection against pertussis. J Infect Dis 181 (2000), 1010–1013.
66. Heininger, U, Riffelmann, M, Bär, G, Rudin, C, von König, CH, The protective role of maternally derived antibodies against Bordetella pertussis in young infants. Pediatr Infect Dis J 32 (2013), 695–698.
67. Maertens, K, Hoang, TH, Caboré, RN, Leuridan, E, Avidity of maternal pertussis antibodies after vaccination during pregnancy. Vaccine, 33, 2015, 5489.
68. Steinhoff, MC, Omer, SB, Roy, E, et al. Influenza immunization in pregnancy—antibody responses in mothers and infants. N Engl J Med 362 (2010), 1644–1646.
69. Eick, AA, Uyeki, TM, Klimov, A, et al. Maternal influenza vaccination and effect on influenza virus infection in young infants. Arch Pediatr Adolesc Med 165 (2011), 104–111.
70. Abu Raya, B, Srugo, I, Kessel, A, et al. The induction of breast milk pertussis specific antibodies following gestational tetanus-diphtheria-acellular pertussis vaccination. Vaccine 32 (2014), 5632–5637.
71. De Schutter, S, Maertens, K, Baerts, L, De Meester, I, Van Damme, P, Leuridan, E, Quantification of vaccine-induced antipertussis toxin secretory IgA antibodies in breast milk: comparison of different vaccination strategies in women. Pediatr Infect Dis J 34 (2015), e149–e152.
72. Quinello, C, Quintilio, W, Carneiro-Sampaio, M, Palmeira, P, Passive acquisition of protective antibodies reactive with Bordetella pertussis in newborns via placental transfer and breast-feeding. Scand J Immunol 72 (2010), 66–73.
73. Elahi, S, Buchanan, RM, Babiuk, LA, Gerdts, V, Maternal immunity provides protection against pertussis in newborn piglets. Infect Immun 74 (2006), 2619–2627.
74. Oda, M, Cowell, JL, Burstyn, DG, Thaib, S, Manclark, CR, Antibodies to Bordetella pertussis in human colostrum and their protective activity against aerosol infection of mice. Infect Immun 47 (1985), 441–445.
75. Schlaudecker, EP, Steinhoff, MC, Omer, SB, et al. IgA and neutralizing antibodies to influenza a virus in human milk: a randomized trial of antenatal influenza immunization. PLoS One, 8, 2013, e70867.
76. Amirthalingam, G, Andrews, N, Campbell, H, et al. Effectiveness of maternal pertussis vaccination in England: an observational study. Lancet 384 (2014), 1521–1528.
77. Dabrera, G, Amirthalingam, G, Andrews, N, et al. A case-control study to estimate the effectiveness of maternal pertussis vaccination in protecting newborn infants in England and Wales, 2012–2013. Clin Infect Dis 60 (2015), 333–337.
78. Ortiz, JR, Englund, JA, Neuzil, KM, Influenza vaccine for pregnant women in resource-constrained countries: a review of the evidence to inform policy decisions. Vaccine 29 (2011), 4439–4452.
79. Zaman, K, Roy, E, Arifeen, SE, et al. Effectiveness of maternal influenza immunization in mothers and infants. N Engl J Med 359 (2008), 1555–1564.
80. Poehlling, KA, Szilagyi, PG, Staat, MA, et al. Impact of maternal immunization on influenza hospitalizations in infants. Am J Obstet Gynecol 204:6 suppl 1 (2011), S141–S148.
81. Thompson, M, Williams, J, Naleway, A, et al. The pregnancy and influenza project: design of an observational case-cohort study to evaluate influenza burden and vaccine effectiveness among pregnant women and their infants. Am J Obstet Gynecol 204:6 suppl 1 (2011), S69–S76.
82. Puleston, RL, Bugg, G, Hoschler, K, et al. Observational study to investigate vertically acquired passive immunity in babies of mothers vaccinated against H1N1v during pregnancy. Health Technol Assess 14 (2010), 1–82.
83. Benowitz, I, Esposito, DB, Gracey, KD, Shapiro, ED, Vázquez, M, Influenza vaccine given to pregnant women reduces hospitalization due to influenza in their infants. Clin Infect Dis 51 (2010), 1355–1361.
84. Omer, SB, Richards, JL, Madhi, SA, et al. Three randomized trials of maternal influenza immunization in Mali, Nepal, and South Africa: methods and expectations. Vaccine 33 (2015), 3801–3812.
85. Englund, JA, Anderson, EL, Reed, GF, et al. The effect of maternal antibody on the serologic response and the incidence of adverse reactions after primary immunization with acellular and whole-cell pertussis vaccines combined with diphtheria and tetanus toxoids. Pediatrics 96 (1995), 580–584.
86. Booy, R, Aitken, SJ, Taylor, S, et al. Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age. Lancet 339 (1992), 507–510.
87. Belloni, C, De Silvestri, A, Tinelli, C, et al. Immunogenicity of a three-component acellular pertussis vaccine administered at birth. Pediatrics 111 (2003), 1042–1045.
88. Wood, N, McIntyre, P, Marshall, H, Roberton, D, Acellular pertussis vaccine at birth and one month induces antibody responses by two months of age. Pediatr Infect Dis J 29 (2010), 209–215.
89. Jones, C, Pollock, L, Barnett, SM, Battersby, A, Kampmann, B, The relationship between concentration of specific antibody at birth and subsequent response to primary immunization. Vaccine 32 (2014), 996–1002.
90. Ladhani, SN, Andrews, NJ, Southern, J, et al. Antibody responses after primary immunization in infants born to women receiving a pertussis-containing vaccine during pregnancy: single arm observational study with a historical comparator. Clin Infect Dis 61 (2015), 1637–1644.
91. Maertens, K, Caboré, RN, Huygen, K, et al. Pertussis vaccination during pregnancy in Belgium: follow-up of infants until 1 month after the fourth infant pertussis vaccination at 15 months of age. Vaccine 34 (2016), 3613–3619.
92. Niewiesk, S, Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies. Front Immunol, 5, 2014, 446.
93. Faucette, AN, Unger, BL, Gonik, B, Chen, K, Maternal vaccination: moving the science forward. Hum Reprod Update 21 (2015), 119–135.
94. Siegrist, CA, Mechanisms by which maternal antibodies influence infant vaccine responses: review of hypotheses and definition of main determinants. Vaccine, 21, 2003, 3406.
95. Halasa, NB, Gerber, MA, Chen, Q, Wright, PF, Edwards, KM, Safety and immunogenicity of trivalent inactivated influenza vaccine in infants. J Infect Dis 197 (2008), 1448–1454.
96. Bischoff, AL, Følsgaard, NV, Vissing, NH, Birch, S, Brix, S, Bisgaard, H, Airway mucosal immune-suppression in neonates of mothers receiving A(H1N1)pnd09 vaccination during pregnancy. Pediatr Infect Dis J 34 (2015), 84–90.
97. Rastogi, D, Wang, C, Mao, X, Lendor, C, Rothman, PB, Miller, RL, Antigen-specific immune responses to influenza vaccine in utero. J Clin Invest 117 (2007), 1637–1646.
98. Talbot, EA, Brown, KH, Kirkland, KB, Baughman, AL, Halperin, SA, Broder, KR, The safety of immunizing with tetanus-diphtheria-acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine 28 (2010), 8001–8007.
99. Kharbanda, EO, Vazquez-Benitez, G, Lipkind, HS, et al. Evaluation of the association of maternal pertussis vaccination with obstetric events and birth outcomes. JAMA 312 (2014), 1897–1904.
100. Zheteyeva, YA, Moro, PL, Tepper, NK, et al. Adverse event reports after tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines in pregnant women. Am J Obstet Gynecol 207 (2012), 59.e1–59.e7.
101. Shakib, JH, Korgenski, K, Sheng, X, Varner, MW, Pavia, AT, Byington, CL, Tetanus, diphtheria, acellular pertussis vaccine during pregnancy: pregnancy and infant health outcomes. J Pediatr 163 (2013), 1422–1426 e4.
102. Donegan, K, King, B, Bryan, P, Safety of pertussis vaccination in pregnant women in UK: observational study. BMJ, 349, 2014, g4219.
103. Morgan, JL, Baggari, SR, McIntire, DD, Sheffield, JS, Pregnancy outcomes after antepartum tetanus, diphtheria, and acellular pertussis vaccination. Obstet Gynecol 125 (2015), 1433–1438.
104. Centers for Disease Control and Prevention. Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine (Tdap) in pregnant women and persons who have or anticipate having close contact with an infant aged <12 months—Advisory Committee on Immunization Practices (ACIP), 2011. MMWR Morb Mortal Wkly Rep 60 (2011), 1424–1426.
105. Vizzotti, C, Neyro, S, Katz, N, et al. Maternal immunization in Argentina: a storyline from the prospective of a middle income country. Vaccine 33 (2015), 6413–6419.
106. Datwani, H, Moro, PL, Harrington, T, Broder, KR, Chorioamnionitis following vaccination in the vaccine adverse event reporting system. Vaccine 33 (2015), 3110–3113.
107. Sukumaran, L, McCarthy, NL, Kharbanda, EO, et al. Association of Tdap vaccination with acute events and adverse birth outcomes among pregnant women with prior tetanus-containing immunizations. JAMA 314 (2015), 1581–1587.
108. Halperin, SA, Sweet, L, Baxendale, D, et al. How soon after a prior tetanus-diphtheria vaccination can one give adult formulation tetanus-diphtheria-acellular pertussis vaccine?. Pediatr Infect Dis J 25 (2006), 195–200.
109. Munoz, FM, Eckert, LO, Katz, MA, et al. Key terms for the assessment of the safety of vaccines in pregnancy: results of a global consultative process to initiate harmonization of adverse event definitions. Vaccine 33 (2015), 6441–6452.
110. Trotta, F, Da Cas, R, Spila Alegiani, S, et al. Evaluation of safety of A/H1N1 pandemic vaccination during pregnancy: cohort study. BMJ, 348, 2014, g3361.
111. Nordin, JD, Kharbanda, EO, Vazquez Benitez, G, Lipkind, H, Vellozzi, C, Destefano, F, Maternal influenza vaccine and risks for preterm or small for gestational age birth. J Pediatr 164 (2014), 1051–1057 e2.
112. Moro, PL, Museru, OI, Broder, K, et al. Safety of influenza A (H1N1) 2009 live attenuated monovalent vaccine in pregnant women. Obstet Gynecol 122 (2013), 1271–1278.
113. Chambers, CD, Johnson, D, Xu, R, et al. Risks and safety of pandemic H1N1 influenza vaccine in pregnancy: birth defects, spontaneous abortion, preterm delivery, and small for gestational age infants. Vaccine 31 (2013), 5026–5032.
114. Chavant, F, Ingrand, I, Jonville-Bera, AP, et al. The PREGVAXGRIP study: a cohort study to assess foetal and neonatal consequences of in utero exposure to vaccination against A(H1N1)v2009 influenza. Eur J Epidemiol 28 (2013), 579–588.
115. Richards, JL, Hansen, C, Bredfeldt, C, et al. Neonatal outcomes after antenatal influenza immunization during the 2009 H1N1 influenza pandemic: impact on preterm birth, birth weight, and small for gestational age birth. Clin Infect Dis 56 (2013), 1216–1222.
116. Sheffield, JS, Greer, LG, Rogers, VL, et al. Effect of influenza vaccination in the first trimester of pregnancy. Obstet Gynecol 120 (2012), 532–537.
117. Pasternak, B, Svanström, H, Mølgaard-Nielsen, D, et al. Risk of adverse fetal outcomes following administration of a pandemic influenza A(H1N1) vaccine during pregnancy. JAMA 308 (2012), 165–174.
118. Fell, DB, Sprague, AE, Liu, N, et al. H1N1 influenza vaccination during pregnancy and fetal and neonatal outcomes. Am J Public Health 102 (2012), e33–e40.
119. Moro, PL, Broder, K, Zheteyeva, Y, et al. Adverse events following administration to pregnant women of influenza A (H1N1) 2009 monovalent vaccine reported to the vaccine adverse event reporting system. Am J Obstet Gynecol, 205, 2011, 473 e1–e9.
120. Toback, SL, Beigi, R, Tennis, P, Sifakis, F, Calingaert, B, Ambrose, CS, Maternal outcomes among pregnant women receiving live attenuated influenza vaccine. Influenza Other Respir Viruses 6 (2012), 44–51.
121. Moro, PL, Broder, K, Zheteyeva, Y, et al. Adverse events in pregnant women following administration of trivalent inactivated influenza vaccine and live attenuated influenza vaccine in the vaccine adverse event reporting system, 1990–2009. Am J Obstet Gynecol 204 (2011), 146.e1–146.e7.
122. Macias, AE, Precioso, AR, Falsey, AR, The global influenza initiative recommendations for the vaccination of pregnant women against seasonal influenza. Influenza Other Respir Viruses 9:suppl 1 (2015), 31–37.
123. Regan, AK, Tracey, LE, Blyth, CC, Richmond, PC, Effler, PV, A prospective cohort study assessing the reactogenicity of pertussis and influenza vaccines administered during pregnancy. Vaccine 34 (2016), 2299–2304.
124. Bratton, KN, Wardle, MT, Orenstein, WA, Omer, SB, Maternal influenza immunization and birth outcomes of stillbirth and spontaneous abortion: a systematic review and meta-analysis. Clin Infect Dis 60 (2015), e11–e19.
125. Omer, SB, Goodman, D, Steinhoff, MC, et al. Maternal influenza immunization and reduced likelihood of prematurity and small for gestational age births: a retrospective cohort study. PLoS Med, 8, 2011, e1000441.
126. Regan, AK, Klerk, Nd, Moore, HC, Omer, SB, Shellam, G, Effler, PV, Effectiveness of seasonal trivalent influenza vaccination against hospital-attended acute respiratory infections in pregnant women: a retrospective cohort study. Vaccine 34 (2016), 3649–3656.
127. Olsen, SJ, Mirza, SA, Vonglokham, P, et al. The effect of influenza vaccination on birth outcomes in a cohort of pregnant women in Lao PDR, 2014–2015. Clin Infect Dis 63 (2016), 487–494.
128. Tapia, MD, Sow, SO, Tamboura, B, et al. Maternal immunization with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. Lancet Infect Dis 16 (2016), 1026–1035.
129. Hutcheon, JA, Fell, DB, Jackson, ML, et al. Detectable risks in studies of the fetal benefits of maternal influenza vaccination. Am J Epidemiol 184 (2016), 227–232.
130. Vazquez-Benitez, G, Kharbanda, EO, Naleway, AL, et al. Risk of preterm or small-for-gestational-age birth after influenza vaccination during pregnancy: caveats when conducting retrospective observational studies. Am J Epidemiol 184 (2016), 176–186.
131. Savitz, DA, Fell, DB, Ortiz, JR, Bhat, N, Does influenza vaccination improve pregnancy outcome? Methodological issues and research needs. Vaccine 33 (2015), 6430–6435.